ArticleAnnals of surgical oncology2026
Clinical Utility of Oncotype DX Testing in Synchronous Bilateral and Unilateral Multifocal Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe investigated the prevalence, clinicopathological correlates, and therapeutic implications of Oncotype DX recurrence score (RS) differences between synchronous tumors in bilateral and unilateral multifocal breast cancer.
methodsPatients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer who underwent Oncotype DX testing of at least two synchronous tumor foci at a tertiary center between 2015 and 2023 were retrospectively identified. Recurrence score risk-category discordance was defined according to cutoffs from the TAILORx and RxPONDER trials. Multivariable linear regression was used to identify the clinicopathological factors associated with absolute differences in RS. Disease-free survival was estimated by using the Kaplan-Meier method and compared using the log-rank test.
resultsAmong 131 patients (38 bilateral, 93 unilateral multifocal), RS risk-category discordance occurred in 21 and 24.7%, respectively, leading to chemotherapy escalation in half of the discordant cases. In bilateral disease, only the progesterone receptor score difference was significantly associated with the absolute RS difference (β = 1.95; 95% confidence interval [CI], 0.44-3.46; P = 0.013). In unilateral disease, absolute RS difference was independently associated with differences in HER2, progesterone receptor, and estrogen receptor scores (all P < 0.05). Recurrence score correlation between paired tumors was higher in unilateral multifocal than in bilateral disease (r = 0.66 vs. 0.36). Disease-free survival showed a consistent, although nonsignificant, trend toward poorer outcomes in discordant cases across both cohorts.
conclusionsRecurrence score risk-category discordance is frequent in synchronous bilateral and unilateral multifocal breast cancer and often changes adjuvant chemotherapy recommendations. Reliance on single-lesion testing risks missing clinically relevant genomic heterogeneity. Multilesion testing may be warranted in selected patients to optimize treatment selection.
Indexed as
Identifiers
41697472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.